iC9/CAR.19/IL15-transduced CB-NK cells

Drug Profile

iC9/CAR.19/IL15-transduced CB-NK cells

Alternative Names: iC9/CAR.19/IL15-transduced cord blood-NK cells; NK-cells-MD-Anderson-Cancer-Center/Bellicum-Pharmaceuticals

Latest Information Update: 05 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; CAR-T cell therapies; Cell therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Haematological malignancies

Most Recent Events

  • 01 Jun 2017 Phase-I/II clinical trials in Haematological malignancies (Second-line therapy or greater) in USA (IV) (NCT03056339)
  • 07 Mar 2017 University of Texas M.D. Anderson Cancer Center and Bellicum Pharmaceuticals plan a phase I/II trial for B-lymphoid malignancies (Second-line therapy or greater) in USA (NCT03056339)
  • 07 Mar 2017 Preclinical trials in Haematological malignancies in USA before March 2017 (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top